Becker's Healthcare September 29, 2022
Noah Schwartz

Pharmaceutical company Qnovia has raised $17 million in series A funding.

Qnovia specializes in creating inhaled therapeutics used to treat nicotine addiction and cardiopulmonary diseases. The company plans to use the funding to advance its nicotine replacement therapy drug through FDA trials and begin human trials in 2023, according to the Sept. 28 Qnovia news release.

The funding round was led by Blue Ledge Capital.

“This series A closing represents a major milestone...

Today's Sponsors

Teladoc Health

Today's Sponsors

Teladoc Health

Today's Sponsor

Oliver Wyman

Topics: Biotechnology, Investments, Pharma, Pharma / Biotech, Trends
Express Scripts adding Humira biosimilars to formulary
Syndax issues $150M public offering pricing
30 Years Of 340B: Preserving The Health Care Safety Net
'Podnosis': biosimilars' impact on costs, rural healthcare crisis
How Much Could COVID-19 Vaccines Cost the U.S. After Commercialization?